Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
Severe peanut allergy is different from other allergic reactions because it can lead to fatal
reactions and is an invisible disability. There is no cure today. The purpose of this study
is to treat children and adolescents with severe peanut allergy with oral immunotherapy with
peanuts under the protection of anti-IgE (immunoglobulin E) antibodies (omalizumab), and
thereby inducing tolerance to peanuts. The treatment will be monitored by basophil cell
stimulation (CD-sens).